Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
111actual
Sites
40
Countries
France, Germany, Hong Kong +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-06-27 | actual | When the study began enrolling |
| Primary completion | 2026-03-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-09-30 | estimated | The whole study's end, after follow-up |
| First posted | 2023-06-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Hepatocellular Carcinoma
Interventions
- Drug: Durvalumab
- Drug: Tremelimumab
Primary outcomes
what the primary-completion date above is the date OFIncidence of grade 3 or 4 possibly related to treatment adverse events (PRAEs)
measured From the date of first dose of IMP until 6 months after the initiation of study intervention
Objective response rate (ORR)
measured From the first dose of IMP until progression, or the last evaluable assessment in the absence of progression [approx. up to 33 months]
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed